Comparing patients’ and their partners’ preferences for adjuvant chemotherapy in early breast cancer

ObjectivePreferences of women who had completed adjuvant chemotherapy for early breast cancer were compared with those of their partners by determining the smallest benefits they judged sufficient to make adjuvant chemotherapy worthwhile.MethodsForty-six women and their partners were interviewed separately, 3–34 months after completing adjuvant chemotherapy. Preferences were elicited using four sets of validated, hypothetical trade-off scenarios about the possible benefits of adjuvant chemotherapy on survival times (5 and 15 years) and survival rates (65% and 85% at 5 years). Agreement within couples was assessed with the intraclass correlation coefficient (ICC). Associations between baseline characteristics, preferences, and agreement within couples were assessed with linear regression after normal score transformation.ResultsThe mean age of the women was 57 years and of their partners’ was 60. Most couples were married (91%). Benefits of an extra 1 day or 0.1% were judged sufficient to make adjuvant chemotherapy worthwhile by 59–72% of women and 54–59% of partners. Agreement was exact in 35–41% of couples and approximate in 59–83%. Agreement was better for scenarios with a worse prognosis (ICC 0.67 and 0.35) than for scenarios with a better prognosis (ICC 0.13 and 0.05). Having dependent children was associated with partners requiring larger benefits but patients requiring smaller benefits to make adjuvant chemotherapy worthwhile (interaction P = 0.001).ConclusionPatients’ and partners’ preferences for adjuvant chemotherapy differed and were influenced by considerations other than length and quality of life.Practice implicationsClinicians who are aware of these differences can tailor discussions to ensure that all interested parties understand and agree on the goals and benefits of treatment.